Common cholesterol pill may hold key to stopping diabetic kidney failure
NCT ID NCT04929379
Summary
This study is testing if fenofibrate, a generic drug used to lower blood fats, can help protect the kidneys in people with type 1 diabetes who have early signs of kidney damage. It will enroll 40 participants who will take either fenofibrate or a placebo for 18 months to see if the drug can slow the loss of kidney function. The goal is to gather information to design a larger future trial that could confirm if this affordable drug is a new treatment option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC NEPHROPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brehm Center for Diabetes Research / University of Michigan
Ann Arbor, Michigan, 48105, United States
-
Joslin Diabetes Center
Boston, Massachusetts, 02215, United States
-
Lahey Hospital and Medical center
Burlington, Massachusetts, 01805, United States
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
Conditions
Explore the condition pages connected to this study.